NICE recommends Piqray and Trodelvy, maintaining 100% approvals of breast cancer drugs since 2018
An agreement with the companies on the price of 2 breast cancer treatments, Piqray and Trodelvy, has paved the way for NICE to be able to make them available immediately to around 3,450 people on the NHS and maintaining NICE’s 100% approval rate of breast cancer drugs since 2018.
In final draft guidance published today (Thursday 14 July 2022) NICE has recommended Piqray (alpelisib, made by Novartis Pharmaceuticals UK), used with the hormonal therapy fulvestrant, for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated locally advanced or metastatic breast cancer that has grown after treatment with combined hormonal therapy and a cancer growth inhibitor.
Given as a once-a-day tablet, Piqray with fulvestrant is the first targeted treatment for this type of breast cancer that has grown after treatment with combined hormonal therapy and a cancer growth inhibitor. It works by blocking the PI3K enzyme which, when overactivated because of a mutation in the PIK3CA gene, stimulates cancer cells to divide and grow in an uncontrolled fashion. By blocking this enzyme, the aim is to reduce the growth and spread of the cancer.
It is estimated that around 2,800 people are eligible for treatment with Piqray plus fulvestrant.
NICE has also recommended Trodelvy (sacituzumab govitecan, made by Gilead Sciences) for treating locally advanced or metastatic triple negative breast cancer which can’t be removed surgically. It is used after people have had 2 or more lines of systemic therapies, at least one of them for locally advanced or metastatic disease which can’t be removed surgically.
Triple negative breast cancer can be more aggressive than other types of breast cancer and accounts for a quarter of all deaths from breast cancer despite accounting for only 1 in 5 cases. Because triple-negative breast cancer is not sensitive to hormone therapy or molecular targeted therapy, the usual treatment is chemotherapy.
Trodelvy works by targeting the activity of Trop-2 proteins that are present at high levels on the surface of tumour cells. By targeting Trop-2 it delivers the anti-cancer component of the drug directly to tumour cells, preventing them from multiplying and eventually causing them to die.
The clinical trial evidence shows that Trodelvy increases how long people have before their disease gets worse by around 3 months and how long they live by around 5 months compared with chemotherapy. It is estimated that around 650 people with advanced triple negative breast cancer are eligible for treatment with Trodelvy.